CANC

Tema Oncology ETF · NAS

Category Health Care
Expense Ratio 0.75%
Listing Date Aug 15, 2023
Volume 36,311.0
Market Cap (AUM) $44.02M

Performance

-4.29%

-3.99%

-15.26%

-7.15%

-4.78%

YTD

+0.78%

Top Holdings

Name
Symbol
%Assets
Regeneron Pharmaceuticals, Inc.REGN5.96%
AstraZeneca PLCAZN5.63%
Merck & Co., Inc.MRK4.81%
Intellia Therapeutics, Inc.NTLA3.78%
Daiichi Sankyo Company, Limited45683.75%
Amgen Inc.AMGN3.33%
Mereo BioPharma Group plc Sponsored ADRMREO3.32%
Incyte CorporationINCY3.20%
Exelixis, Inc.EXEL3.08%
Illumina, Inc.ILMN2.99%

Advanced Technical Analysis

Technical Analysis of CANC 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declines.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Recent News & Updates

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.